Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- PMID: 33239190
- DOI: 10.1016/j.annonc.2020.07.011
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Keywords: Clinical Practice Guidelines; SCCHN; diagnosis; follow-up; treatment.
Conflict of interest statement
Disclosure JPM reports acting in an advisory role for Merck Serono and MSD; CRL reports acting in an advisory role for Rakuten Medical and MSD. LL reports participation for public speaking/teaching in medical meetings and/or for providing expert opinion in advisory boards for AstraZeneca, Bayer, BMS, Eisai, MSD, Merck Serono, Boehringer Ingelheim, Novartis, Roche, Debiopharm International SA, Sobi, Ipsen, Incyte Biosciences Italy SRL, Doxa Pharma, Amgen, Nanobiotics and GSK. All other authors have declared no potential conflicts of interest.
Republished in
-
Reprint of "Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up".Oral Oncol. 2021 Feb;113:105042. doi: 10.1016/j.oraloncology.2020.105042. Epub 2020 Oct 23. Oral Oncol. 2021. PMID: 33583513 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
